Adam Pleister

TL;DR: This is the largest study to date to evaluate the effect of SDB on post-discharge mortality in patients with AHF and it shows that newly diagnosed CSA and OSA during AHF hospitalization are independently associated with post- disordered breathing mortality.

TL;DR: It is hypothesized that trisomic 21 gene dosage overexpression of Hsa21-derived miRNAs results in the decreased expression of specific target proteins and contribute, in part, to features of the neuronal and cardiac DS phenotype.

TL;DR: Although cardiomyopathy is asymptomatic in the early stages, symptoms are the same as those characteristically seen in any type of heart failure and may include shortness of breath, fatigue, cough, orthopnea, paroxysmal nocturnal dyspnea, and edema.

TL;DR: This study demonstrates by luciferase/target mRNA 3′-untranslated region reporter assays that miR-155 and -802 can regulate the expression of the predicted mRNA target, the methyl-CpG-binding protein (MeCP2), and demonstrates that selective inactivation of Hsa21-derived miRNAs may provide a novel therapeutic tool in the treatment of DS.

TL;DR: It is found that eNOS is dysfunctional in OSA patients pre-treatment, and is a source of endothelial O2(•-) overproduction, and a potentially targetable pathway for treatment of cardiovascular risk in Osa.